Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERT-1: Panitumumab + Chemoradiation in HNSCC
NCT00500760Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2007
- Primary completion
- Mar 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Amgen. Started Oct 2007; status: completed.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00500760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500760.